Agency Forms Undergoing Paperwork Reduction Act Review, 76690-76692 [2015-31104]
Download as PDF
<![CDATA[
76690
Federal Register / Vol. 80, No. 237 / Thursday, December 10, 2015 / Notices
technically feasible. We therefore
cannot find that the New 2010
Requirements that we analyzed under
the full authorization criteria are
inconsistent with section 209 of the Act.
Having found that the New 2010
Requirements satisfy each of the criteria
for full authorization, and having
received no contrary evidence to
contradict this finding, we cannot deny
authorization of the amendments.
mstockstill on DSK4VPTVN1PROD with NOTICES
III. Decision
The Administrator has delegated the
authority to grant California section
209(e) authorizations to the Assistant
Administrator for Air and Radiation.
After evaluating CARB’s amendments to
its Portable Engine ATCM regulations
described above and CARB’s
submissions for EPA review, EPA is
granting a within-the-scope
authorization for the Portable Engine
ATCM 2007, 2009, and 2010
Amendments, other than the New 2010
Requirements (as specified above). In
addition, EPA is granting a full
authorization for the New 2010
Requirements.
This decision will affect persons in
California and those manufacturers and/
or owners/operators nationwide who
must comply with California’s
requirements. In addition, because other
states may adopt California’s standards
for which a section 209(e)(2)(A)
authorization has been granted if certain
criteria are met, this decision would
also affect those states and those
persons in such states. See CAA section
209(e)(2)(B). For these reasons, EPA
determines and finds that this is a final
action of national applicability, and also
a final action of nationwide scope or
effect for purposes of section 307(b)(1)
of the Act. Pursuant to section 307(b)(1)
of the Act, judicial review of this final
action may be sought only in the United
States Court of Appeals for the District
of Columbia Circuit. Petitions for review
must be filed by February 8, 2016.
Judicial review of this final action may
not be obtained in subsequent
enforcement proceedings, pursuant to
section 307(b)(2) of the Act.
IV. Statutory and Executive Order
Reviews
As with past authorization and waiver
decisions, this action is not a rule as
defined by Executive Order 12866.
Therefore, it is exempt from review by
the Office of Management and Budget as
required for rules and regulations by
Executive Order 12866.
In addition, this action is not a rule
as defined in the Regulatory Flexibility
Act, 5 U.S.C. 601(2). Therefore, EPA has
not prepared a supporting regulatory
VerDate Sep<11>2014
19:33 Dec 09, 2015
Jkt 238001
flexibility analysis addressing the
impact of this action on small business
entities.
Further, the Congressional Review
Act, 5 U.S.C. 801, et seq., as added by
the Small Business Regulatory
Enforcement Fairness Act of 1996, does
not apply because this action is not a
rule for purposes of 5 U.S.C. 804(3).
Dated: December 1, 2015.
Janet G. McCabe,
Acting Assistant Administrator, Office of Air
and Radiation.
[FR Doc. 2015–31043 Filed 12–9–15; 8:45 am]
insurance plans, including designing
plans, assisting in the implementation
of plans, providing administrative
services to plans, and developing
employee communication programs for
plans, pursuant to sections 225.28(b)(5),
(b)(6)(ii), (b)(9)(ii) and (b)(14)(i),
respectively.
Board of Governors of the Federal Reserve
System, December 7, 2015.
Michael J. Lewandowski,
Associate Secretary of the Board.
[FR Doc. 2015–31109 Filed 12–9–15; 8:45 am]
BILLING CODE 6210–01–P
BILLING CODE 6560–50–P
FEDERAL RESERVE SYSTEM
Notice of Proposals To Engage in or
To Acquire Companies Engaged in
Permissible Nonbanking Activities
The companies listed in this notice
have given notice under section 4 of the
Bank Holding Company Act (12 U.S.C.
1843) (BHC Act) and Regulation Y, (12
CFR part 225) to engage de novo, or to
acquire or control voting securities or
assets of a company, including the
companies listed below, that engages
either directly or through a subsidiary or
other company, in a nonbanking activity
that is listed in § 225.28 of Regulation Y
(12 CFR 225.28) or that the Board has
determined by Order to be closely
related to banking and permissible for
bank holding companies. Unless
otherwise noted, these activities will be
conducted throughout the United States.
Each notice is available for inspection
at the Federal Reserve Bank indicated.
The notice also will be available for
inspection at the offices of the Board of
Governors. Interested persons may
express their views in writing on the
question whether the proposal complies
with the standards of section 4 of the
BHC Act.
Unless otherwise noted, comments
regarding the notices must be received
at the Reserve Bank indicated or the
offices of the Board of Governors not
later than December 28, 2015.
A. Federal Reserve Bank of
Minneapolis (Jacquelyn K. Brunmeier,
Assistant Vice President) 90 Hennepin
Avenue, Minneapolis, Minnesota
55480–0291:
1. State Bankshares, Inc., Fargo, North
Dakota to acquire an additional 51
percent of the voting shares of Discovery
Benefits, Inc., Fargo, North Dakota, and
indirectly acquire additional voting
shares of Discovery Benefits, Inc., Fargo,
North Dakota, and thereby engage in
providing consulting services to
employee benefit, compensation and
PO 00000
Frm 00037
Fmt 4703
Sfmt 4703
FEDERAL RETIREMENT THRIFT
INVESTMENT BOARD
Sunshine Act; Notice of Meeting/
Correction—Addition of #6
10:00 a.m. (Eastern
Time) December 14, 2015 (Telephonic)
PLACE: 10th Floor Board Meeting Room,
77 K Street NE., Washington, DC 20002.
STATUS: Parts will be open to the public
and parts will be closed to the public.
MATTERS TO BE CONSIDERED:
TIME AND DATE:
Open to the Public
1. Approval of the Minutes for the
November 25, 2015 Board Member
Meeting
2. Monthly Reports
(a) Monthly Participant Activity Report
(b) Monthly Investment Performance
Report
(c) Legislative Report
3. Quarterly Metrics Report
4. OGC Report and Annual Presentation
Closed to the Public
5. Security
6. Personnel
CONTACT PERSON FOR MORE INFORMATION:
Kimberly Weaver, Director, Office of
External Affairs, (202) 942–1640.
Dated: December 8, 2015.
James Petrick,
General Counsel, Federal Retirement Thrift
Investment Board.
[FR Doc. 2015–31268 Filed 12–8–15; 4:15 pm]
BILLING CODE 6760–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[30Day–16–0307]
Agency Forms Undergoing Paperwork
Reduction Act Review
The Centers for Disease Control and
Prevention (CDC) has submitted the
E:\FR\FM\10DEN1.SGM
10DEN1
Federal Register / Vol. 80, No. 237 / Thursday, December 10, 2015 / Notices
following information collection request
to the Office of Management and Budget
(OMB) for review and approval in
accordance with the Paperwork
Reduction Act of 1995. The notice for
the proposed information collection is
published to obtain comments from the
public and affected agencies.
Written comments and suggestions
from the public and affected agencies
concerning the proposed collection of
information are encouraged. Your
comments should address any of the
following: (a) Evaluate whether the
proposed collection of information is
necessary for the proper performance of
the functions of the agency, including
whether the information will have
practical utility; (b) Evaluate the
accuracy of the agencies estimate of the
burden of the proposed collection of
information, including the validity of
the methodology and assumptions used;
(c) Enhance the quality, utility, and
clarity of the information to be
collected; (d) Minimize the burden of
the collection of information on those
who are to respond, including through
the use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic submission of
responses; and (e) Assess information
collection costs.
To request additional information on
the proposed project or to obtain a copy
of the information collection plan and
instruments, call (404) 639-7570 or send
an email to omb@cdc.gov. Written
comments and/or suggestions regarding
the items contained in this notice
should be directed to the Attention:
CDC Desk Officer, Office of Management
and Budget, Washington, DC 20503 or
by fax to (202) 395-5806. Written
comments should be received within 30
days of this notice.
mstockstill on DSK4VPTVN1PROD with NOTICES
Proposed Project
The Gonococcal Isolate Surveillance
Project (GISP, OMB No. 0920–0307 exp.
08/31/2016) – Extension – National
Center for HIV/AIDS, Viral Hepatitis,
STD, and TB Prevention (NCHHSTP),
Centers for Disease Control and
Prevention (CDC).
Background and Brief Description
The objectives of GISP are: (1) To
monitor trends in antibiotic resistance
VerDate Sep<11>2014
19:33 Dec 09, 2015
Jkt 238001
of Neisseria gonorrhoeae strains in the
United States and (2) to characterize
resistant specimens. Surveillance of N.
gonorrhoeae antibiotic resistance is
important because: (1) Nearly all
gonococcal infections are treated
empirically (meaning that healthcare
providers have to decide how to treat
their patients without having resistance
testing results for individual patients
upon which to base clinical decisionmaking) and susceptibility/resistance
testing data are not routinely available
in clinical practice; (2) N. gonorrhoeae
has consistently demonstrated the
ability to develop resistance to the
antibiotics used for treatment; (3)
effective treatment of gonorrhea is a
critical component of gonorrhea control
and prevention, and (4) untreated or
inadequately treated gonorrhea can
cause serious reproductive health
complications.
GISP is the only source in the United
States of national, regional, and sitespecific gonococcal antibiotic resistance
information. GISP provides information
to support informed and scientificallybased treatment recommendations.
GISP was established in 1986 as a
voluntary surveillance project and now
involves 5 regional laboratories and 30
publicly funded sexually transmitted
disease (STD) clinics around the
country. The STD clinics submit up to
25 gonococcal specimens (or isolates)
per month to the regional laboratories,
which measure the ability of the
specimens to resist the effects of
multiple antibiotics. Limited
demographic and clinical information
corresponding to the isolates (and that
do not allow identification of the
patient) are submitted directly by the
clinics to CDC.
During 1986–2015, GISP has
demonstrated the ability to effectively
achieve its objectives. GISP has tracked
penicillin and tetracycline resistance
and identified the emergence of
fluoroquinolone resistance. Increased
prevalence of fluoroquinolone-resistant
N. gonorrhoeae (QRNG), as documented
by GISP data, prompted CDC to update
treatment recommendations for
gonorrhea in CDC’s Sexually
Transmitted Diseases Treatment
Guidelines, 2006 and to release an
MMWR article stating that CDC no
longer recommended fluoroquinolones
for treatment of gonococcal infections.
PO 00000
Frm 00038
Fmt 4703
Sfmt 4703
76691
Information from GISP thus allowed
public health officials to change
treatment recommendations before
resistance became widespread, ensuring
that patients were able to be
successfully treated. Recently, GISP
isolates demonstrated increasing
minimum inhibitory concentrations of
cefixime, which can be an early warning
of impending resistance. This
worrisome trend prompted CDC to again
update treatment recommendations and
no longer recommend the use of
cefixime as first-line treatment for
gonococcal infections.
Under the GISP protocol, each of the
30 clinics submit an average of 20
isolates per clinic per month (i.e. 240
times per year) recorded on Form 1:
Demographic/Clinical Data. The
estimated time for clinical personnel to
abstract data for Form 1: Demographic/
Clinical Data is 11 minutes per
response.
Each of the 5 Regional laboratories
receives and processes approximately
20 isolates from each referring clinic per
month (i.e. 121 isolates per regional
laboratory per month [based on 2011
specimen volume]) using Form 2:
Antimicrobial Susceptibility Testing.
For Form 2: Antimicrobial
Susceptibility Testing, the annual
frequency of responses per respondent
is 1452 (121 isolates x 12 months).
Based on previous laboratory
experience, the estimated burden of
completing Form 2 for each
participating laboratory is 1 hour per
response, which includes the time
required for laboratory processing of the
patient’s isolate, gathering and
maintaining the data needed, and
completing and reviewing the collection
of information. For Form 3: Control
Strain Susceptibility Testing, a
‘‘response’’ is defined as the processing
and recording of Regional laboratory
data for a set of 7 control strains. It takes
approximately 12 minutes to process
and record the Regional laboratory data
on Form 3 for one set of 7 control
strains, of which there are 4 sets. The
number of responses per respondent is
48 (4 sets x 12 months).
The total estimated annual burden
hours are 8,628. Respondents receive
federal funds to participate in this
project. There are no additional costs to
respondents other than their time.
E:\FR\FM\10DEN1.SGM
10DEN1
76692
Federal Register / Vol. 80, No. 237 / Thursday, December 10, 2015 / Notices
ESTIMATE OF ANNUALIZED BURDEN HOURS
Number of
respondents
Type of respondents
Form name
Clinic ...............................................................
Laboratory .......................................................
Demographic Clinical Data Form 1 ................
Antimicrobial Susceptibility Testing Form 2 ...
Control Strain Susceptibility Testing Form 3
Leroy A. Richardson,
Chief, Information Collection Review Office,
Office of Scientific Integrity, Office of the
Associate Director for Science, Office of the
Director, Centers for Disease Control and
Prevention.
[FR Doc. 2015–31104 Filed 12–9–15; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[30Day–16–0488]
mstockstill on DSK4VPTVN1PROD with NOTICES
Agency Forms Undergoing Paperwork
Reduction Act Review
The Centers for Disease Control and
Prevention (CDC) has submitted the
following information collection request
to the Office of Management and Budget
(OMB) for review and approval in
accordance with the Paperwork
Reduction Act of 1995. The notice for
the proposed information collection is
published to obtain comments from the
public and affected agencies.
Written comments and suggestions
from the public and affected agencies
concerning the proposed collection of
information are encouraged. Your
comments should address any of the
following: (a) Evaluate whether the
proposed collection of information is
necessary for the proper performance of
the functions of the agency, including
whether the information will have
practical utility; (b) Evaluate the
accuracy of the agencies estimate of the
burden of the proposed collection of
information, including the validity of
the methodology and assumptions used;
(c) Enhance the quality, utility, and
clarity of the information to be
collected; (d) Minimize the burden of
the collection of information on those
who are to respond, including through
the use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic submission of
responses; and (e) Assess information
collection costs.
VerDate Sep<11>2014
19:33 Dec 09, 2015
Jkt 238001
To request additional information on
the proposed project or to obtain a copy
of the information collection plan and
instruments, call (404) 639–7570 or
send an email to omb@cdc.gov. Written
comments and/or suggestions regarding
the items contained in this notice
should be directed to the Attention:
CDC Desk Officer, Office of Management
and Budget, Washington, DC 20503 or
by fax to (202) 395–5806. Written
comments should be received within 30
days of this notice.
Proposed Project
Restrictions on Interstate Travel of
Persons (42 CFR part 70) (OMB Control
No. 0920–0488, expiration, 3/31/
2016)— Revision—Division of Global
Migration and Quarantine, National
Center for Emerging Zoonotic and
Infectious Diseases, Centers for Disease
Control and Prevention (CDC).
Background and Brief Description
This revision to an existing
information collection request is
intended to ensure that CDC can
continue collect pertinent information
related to communicable disease or
deaths that occur aboard conveyances
during interstate travel within the
United States, as authorized under 42
Code of Federal Regulations (CFR) part
70. Additionally, CDC is requesting
approval to use the Passenger Locator
Form in the event that travelers on
domestic flights within the United
States need to be contacted for public
health follow-up.
The intended use of the information
is to ensure that CDC can assess and
respond to reports of communicable
disease or death that occur on
conveyances engaged in interstate
travel, and assist state and local health
authorities if an illness or death occurs
that poses a risk to public health.
Generally, the primary source of this
information is aircraft and travelers
moving within the United States.
This revision makes several
modification to this information
collection. They are as follows: In
current practice, CDC does not process
applications for travel permits using the
Restriction On Travel Of Persons
Multipurpose Application Form Under
PO 00000
Frm 00039
Fmt 4703
Sfmt 4703
30
5
5
Number of
responses per
respondent
240
1,452
48
Average
burden per
response
(in hours)
11/60
1
12/60
the Provisions of 42 CFR part 70 (aka Ill
Person Travel Permit); therefore the
information collections under 42 CFR
70.3, Application to the State of
destination for a permit, Copy of
material submitted by applicant and
permit issued by State health authority
(Attending physician), and Copy of
material submitted by applicant and
permit issued by State health authority
(State health authority) are being
removed. Similarly, information
collections under 42 CFR 70.5,
Application for a permit to move from
State to State while in the
communicable period (Attending
physician) and Application for a permit
to move from State to State while in the
communicable period (Traveler) are also
being removed. The issuance of travel
restrictions is a collaborative process
between public health partners, e.g.
state health departments, the
Department of Homeland Security, and
CDC. There is no standardized
collection of information involved. This
change results in the removal of the
information collections under 42 CFR
70.3 and 70.5 from the list of
information collections as well as the
removal of the associated burden.
Reports of communicable disease or
death from domestic conveyances are
almost always submitted electronically
to meet requirements of 42 CFF 70.4, so
the current hard copy Master of Vessel
or Conveyance Illness Report, which
was constructed to be used by masters
of vessels to comply with 42 CFR 70.4,
has been rendered obsolete. In addition,
CDC has issued guidance stating that
reports to CDC, instead of local health
authorities, regarding domestic reports
of communicable disease or death on
board conveyances meet the
requirements of the regulation;
therefore, information collections
related to copies of the report sent by
masters of vessels to state health
departments are no longer necessary.
The only remaining information
collection under 42 CFR 70.4 is Report
by the master of a vessel or person in
charge of conveyance of the incidence of
a communicable disease occurring
while in interstate travel.
E:\FR\FM\10DEN1.SGM
10DEN1
]]>Agencies
[Federal Register Volume 80, Number 237 (Thursday, December 10, 2015)]
[Notices]
[Pages 76690-76692]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-31104]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[30Day-16-0307]
Agency Forms Undergoing Paperwork Reduction Act Review
The Centers for Disease Control and Prevention (CDC) has submitted
the
[[Page 76691]]
following information collection request to the Office of Management
and Budget (OMB) for review and approval in accordance with the
Paperwork Reduction Act of 1995. The notice for the proposed
information collection is published to obtain comments from the public
and affected agencies.
Written comments and suggestions from the public and affected
agencies concerning the proposed collection of information are
encouraged. Your comments should address any of the following: (a)
Evaluate whether the proposed collection of information is necessary
for the proper performance of the functions of the agency, including
whether the information will have practical utility; (b) Evaluate the
accuracy of the agencies estimate of the burden of the proposed
collection of information, including the validity of the methodology
and assumptions used; (c) Enhance the quality, utility, and clarity of
the information to be collected; (d) Minimize the burden of the
collection of information on those who are to respond, including
through the use of appropriate automated, electronic, mechanical, or
other technological collection techniques or other forms of information
technology, e.g., permitting electronic submission of responses; and
(e) Assess information collection costs.
To request additional information on the proposed project or to
obtain a copy of the information collection plan and instruments, call
(404) 639-7570 or send an email to omb@cdc.gov. Written comments and/or
suggestions regarding the items contained in this notice should be
directed to the Attention: CDC Desk Officer, Office of Management and
Budget, Washington, DC 20503 or by fax to (202) 395-5806. Written
comments should be received within 30 days of this notice.
Proposed Project
The Gonococcal Isolate Surveillance Project (GISP, OMB No. 0920-
0307 exp. 08/31/2016) - Extension - National Center for HIV/AIDS, Viral
Hepatitis, STD, and TB Prevention (NCHHSTP), Centers for Disease
Control and Prevention (CDC).
Background and Brief Description
The objectives of GISP are: (1) To monitor trends in antibiotic
resistance of Neisseria gonorrhoeae strains in the United States and
(2) to characterize resistant specimens. Surveillance of N. gonorrhoeae
antibiotic resistance is important because: (1) Nearly all gonococcal
infections are treated empirically (meaning that healthcare providers
have to decide how to treat their patients without having resistance
testing results for individual patients upon which to base clinical
decision-making) and susceptibility/resistance testing data are not
routinely available in clinical practice; (2) N. gonorrhoeae has
consistently demonstrated the ability to develop resistance to the
antibiotics used for treatment; (3) effective treatment of gonorrhea is
a critical component of gonorrhea control and prevention, and (4)
untreated or inadequately treated gonorrhea can cause serious
reproductive health complications.
GISP is the only source in the United States of national, regional,
and site-specific gonococcal antibiotic resistance information. GISP
provides information to support informed and scientifically-based
treatment recommendations.
GISP was established in 1986 as a voluntary surveillance project
and now involves 5 regional laboratories and 30 publicly funded
sexually transmitted disease (STD) clinics around the country. The STD
clinics submit up to 25 gonococcal specimens (or isolates) per month to
the regional laboratories, which measure the ability of the specimens
to resist the effects of multiple antibiotics. Limited demographic and
clinical information corresponding to the isolates (and that do not
allow identification of the patient) are submitted directly by the
clinics to CDC.
During 1986-2015, GISP has demonstrated the ability to effectively
achieve its objectives. GISP has tracked penicillin and tetracycline
resistance and identified the emergence of fluoroquinolone resistance.
Increased prevalence of fluoroquinolone-resistant N. gonorrhoeae
(QRNG), as documented by GISP data, prompted CDC to update treatment
recommendations for gonorrhea in CDC's Sexually Transmitted Diseases
Treatment Guidelines, 2006 and to release an MMWR article stating that
CDC no longer recommended fluoroquinolones for treatment of gonococcal
infections. Information from GISP thus allowed public health officials
to change treatment recommendations before resistance became
widespread, ensuring that patients were able to be successfully
treated. Recently, GISP isolates demonstrated increasing minimum
inhibitory concentrations of cefixime, which can be an early warning of
impending resistance. This worrisome trend prompted CDC to again update
treatment recommendations and no longer recommend the use of cefixime
as first-line treatment for gonococcal infections.
Under the GISP protocol, each of the 30 clinics submit an average
of 20 isolates per clinic per month (i.e. 240 times per year) recorded
on Form 1: Demographic/Clinical Data. The estimated time for clinical
personnel to abstract data for Form 1: Demographic/Clinical Data is 11
minutes per response.
Each of the 5 Regional laboratories receives and processes
approximately 20 isolates from each referring clinic per month (i.e.
121 isolates per regional laboratory per month [based on 2011 specimen
volume]) using Form 2: Antimicrobial Susceptibility Testing. For Form
2: Antimicrobial Susceptibility Testing, the annual frequency of
responses per respondent is 1452 (121 isolates x 12 months). Based on
previous laboratory experience, the estimated burden of completing Form
2 for each participating laboratory is 1 hour per response, which
includes the time required for laboratory processing of the patient's
isolate, gathering and maintaining the data needed, and completing and
reviewing the collection of information. For Form 3: Control Strain
Susceptibility Testing, a ``response'' is defined as the processing and
recording of Regional laboratory data for a set of 7 control strains.
It takes approximately 12 minutes to process and record the Regional
laboratory data on Form 3 for one set of 7 control strains, of which
there are 4 sets. The number of responses per respondent is 48 (4 sets
x 12 months).
The total estimated annual burden hours are 8,628. Respondents
receive federal funds to participate in this project. There are no
additional costs to respondents other than their time.
[[Page 76692]]
Estimate of Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
Average
Number of Number of burden per
Type of respondents Form name respondents responses per response (in
respondent hours)
----------------------------------------------------------------------------------------------------------------
Clinic................................ Demographic Clinical 30 240 11/60
Data Form 1.
Laboratory............................ Antimicrobial 5 1,452 1
Susceptibility Testing
Form 2.
Control Strain 5 48 12/60
Susceptibility Testing
Form 3.
----------------------------------------------------------------------------------------------------------------
Leroy A. Richardson,
Chief, Information Collection Review Office, Office of Scientific
Integrity, Office of the Associate Director for Science, Office of the
Director, Centers for Disease Control and Prevention.
[FR Doc. 2015-31104 Filed 12-9-15; 8:45 am]
BILLING CODE 4163-18-P
